| (AstraZeneca) D7984C00002 / GOG-3092 / eVOLVECervical | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Womenwith High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical) | Dr Nidhi Kumar-Tyagi | Open to recruitment | NCT06079671 |
| (Merck) MK-2870-020 / GOG-3101 / ENGOT-cx20 / TroFuse-020 | A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) | Dr Nidhi Kumar-Tyagi | Open to recruitment | NCT06459180 |
| (CCTG) VU.2 / STRIVE | STRatIfication of Vulvar Squamous Cell Carcinoma by HPV and p53 Status to Guide Excision: STRIVE Study | Dr Julie My Van Nguyen | Open to recruitment | NCT05576831 |
Find a Trial
Contact Us